The role of radiotherapy in urinary bladder cancer: Current Status

International Braz J Urol

Volumn 38, Issue 2, 2012, Pages 144-153

  Marta, Gustavo Nader ^a   Hanna, Samir Abdallah ^a   Gadia, Rafael ^a,b   Correa, Sebastião Francisco Miranda ^a,c   Silva, Joao Luis Fernandes da ^a   Carvalho, Heloisa de Andrade ^a,d  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b Oncology Center Instituto do Cancer do Estado de Sao Paulo   (Brazil)

^c Hospital da Real e Benemerita Sociedade Portuguesa de Benefi cencia   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Neoplasms; Radiotherapy; Review; Urinary bladder

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

BLADDER TUMOR; CARCINOMA; CYSTECTOMY; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE CARE; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; URINE INCONTINENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; POSTOPERATIVE CARE; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; URINARY INCONTINENCE;

EID: 84865367918     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382012000200002     Document Type: Review

References (60)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. Erratum in: CA Cancer J Clin. 2011;61: 134.
2. American Joint Committee on Cancer. Urinary bladder. In: AJCC Cancer Staging Manual, 7th. New York: Springer-Verlag, 2010; pp. 497-505.
3. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S. et al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-75.
4. Dall'oglio MF, Nesrallah LJ, Rodrigues P, Nesrallah A, Kauffmann JR, Srougi M: The use of absorbable mechanical suture in orthotopic ileal neobladder replacement. Int Braz J Urol. 2000; 26: 288-92.
5. Castillo OA, Abreu SC, Mariano MB, Tefilli MV, Hoyos J, Pinto I, et al.: Complications in laparoscopic radical cys-tectomy. The South American experience with 59 cases. Int Braz J Urol. 2006; 32: 300-5.
6. Stenzl A, Sherif H, Kuczyk M: Radical cystectomy with or-thotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. Int Braz J Urol. 2010; 36: 537-47.
7. Beduschi R, Montie JE: Current indications and new possibilities for organ preservation in carcinoma of the bladder. Int Braz J Urol. 2000; 26: 234-41.
8. Gospodarowicz MK, Warde P: The role of radiation therapy in the management of transitional cell carcinoma of the bladder. Hematol Oncol Clin North Am. 1992; 6: 147-68.
9. Quilty PM, Duncan W: Treatment of superficial (T1) tumours of the bladder by radical radiotherapy. Br J Urol. 1986; 58: 147-52.
10. Sawczuk IS, Olsson CA, deVere White R: The limited usefulness of external beam radiotherapy in the control of su-perficial bladder cancer. Br J Urol. 1988; 61: 330-2.
11. Wolf H, Olsen PR, Højgaard K: Urothelial dysplasia concomitant with bladder tumours: a determinant for future new occurrences in patients treated by full-course radio-therapy. Lancet. 1985; 1: 1005-8.
12. Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, et al.: Radiochemotherapy with cisplatin and 5-flu-orouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 1072-80.
13. Batata MA, Chu FC, Hilaris BS, Lee MZ, Varesko RW, Lee HS, et al.: Preoperative whole pelvis verus true pelvis irradiation and/or cystectomy for bladder cancer. Int J Radiat Oncol Biol Phys. 1981; 7: 1349-55.
14. Batata MA, Chu FC, Hilaris BS, Kim Y, Lee M, Chang B, et al.: Radiation therapy before cystectomy in the management of patients with bladder cancer. Clin Radiol. 1982; 33: 109-14.
15. Spera JA, Whittington R, Littman P, Solin LJ, Wein AJ: A comparison of preoperative radiotherapy regimens for bladder carcinoma. The University of Pennsylvania experience. Cancer. 1988; 61: 255-62.
16. Parsons JT, Million RR: Planned preoperative irradiation in the management of clinical stage B2-C (T3) bladder carcinoma. Int J Radiat Oncol Biol Phys. 1988; 14: 797-810.
17. Abrahamsen JF, Fosså SD: Long-term morbidity after curative radiotherapy for carcinoma of the bladder. A retrospective study. Strahlenther Onkol. 1990; 166: 580-3.
18. Blackard CE, Byar DP: Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder. J Urol. 1972; 108: 875-8.
19. Bloom HJ, Hendry WF, Wallace DM, Skeet RG: Treatment of T3 bladder cancer: controlled trial of pre-operative ra-diotherapy and radical cystectomy versus radical radio-therapy. Br J Urol. 1982; 54: 136-51.
20. Sell A, Jakobsen A, Nerstrøm B, Sørensen BL, Steven K, Barlebo H: Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preop-erative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl. 1991; 138: 193-201.
21. Miller LS: Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer. 1977; 39(2 Suppl): 973-80.
22. Huncharek M, Muscat J, Geschwind JF: Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res. 1998; 18: 1931-4.
23. Dhar NB, Campbell SC, Zippe CD, Derweesh IH, Reuther AM, Fergany A, et al.: Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection. BJU Int. 2006; 98: 1172-5.
24. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, et al.: Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010; 183: 2165-70.
25. Duncan W, Quilty PM: The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986; 7: 299-310.
26. Jenkins BJ, Caulfield MJ, Fowler CG, Badenoch DF, Tiptaft RC, Paris AM, et al.: Reappraisal of the role of radical ra-diotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol. 1988; 62: 343-6.
27. Daehlin L, Haukaas S, Maartmann-Moe H, Medby PC: Survival after radical treatment for transitional cell carcinoma of the bladder. Eur J Surg Oncol. 1999; 25: 66-70.
28. Fossa SD, Aass N, Ous S, Waehre H, Ilner K, Hannisdal E: Survival after curative treatment of muscle-invasive bladder cancer. Acta Oncol. 1996; 35(Suppl 8): 59-65.
29. Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, et al.: Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol On-col. 2007; 25: 303-9.
30. Shipley WU, Rose MA, Perrone TL, Mannix CM, Heney NM, Prout GR Jr.: Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol. 1985; 134: 679-83.
31. Mameghan H, Fisher R, Mameghan J, Brook S: Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys. 1995; 31: 247-54.
32. Langsenlehner T, Döller C, Quehenberger F, Stranzl-La-watsch H, Langsenlehner U, Pummer K, et al.: Treatment results of radiation therapy for muscle-invasive bladder cancer. Strahlenther Onkol. 2010; 186: 203-9.
33. Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al.: Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993; 11: 2150-7.
34. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al.: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or de-finitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996; 14: 2901-7.
35. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawl-ings C, et al.: Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004). J Clin Oncol. 2010; 28(Suppl 15): Abstract # 4517.
36. Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, et al.: Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20: 3061-71.
37. Manoharan M, Soloway MS: Optimal management of the T1G3 bladder cancer. Urol Clin North Am. 2005; 32: 133-45.
38. Soloway MS, Sofer M, Vaidya A: Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol. 2002; 167: 1573-83.
39. Splinter T, Denis L: Restaging procedures, criteria of response, and relationship between pathological response and survival. Semin Oncol. 1990; 17: 606-12.
40. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE: A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2003; 169: 96-100; discussion 100.
41. Peyromaure M, Zerbib M: T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int. 2004; 93: 60-3.
42. May M, Helke C, Nitzke T, Vogler H, Hoschke B: Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int. 2004; 72: 103-11.
43. Caffo O, Fellin G, Graffer U, Mussari S, Tomio L, Galligioni E: Gemcitabine and radiotherapy plus cisplatin after trans-urethral resection as conservative treatment for infiltrat-ing bladder cancer: Long-term cumulative results of 2 prospective single-institution studies. Cancer. 2011; 117: 1190-6.
44. Kotwal S, Munro N: Radiotherapy in localized bladder cancer: what is the evidence? Curr Opin Urol. 2010; 20: 426-31.
45. Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, et al.: Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997; 15: 1022-9.
46. Shipley WU, Kaufman DS, Heney NM, Althausen AF, Ziet-man AL: An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol. 1999; 162: 445-50; discussion 450-1.
47. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al.: Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993; 25: 783-90.
48. Arias F, Domínguez MA, Martínez E, Illarramendi JJ, Miquelez S, Pascual I, et al.: Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys. 2000; 47: 373-8.
49. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al.: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998; 16: 3576-83.
50. Perdonà S, Autorino R, Damiano R, De Sio M, Morrica B, Gallo L, et al.: Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer. 2008; 112: 75-83.
51. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a ran-domised controlled trial. International collaboration of trial-ists. Lancet. 1999; 354: 533-40. Erratum in: Lancet. 1999; 354: 1650.
52. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder et al.: International phase III trial assessing neoadjuvant cispla-tin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 2171-7.
53. Moonen L, vd Voet H, de Nijs R, Horenblas S, Hart AA, Bartelink H: Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys. 1998; 42: 525-30.
54. Pos FJ, Hart G, Schneider C, Sminia P: Radical radiothera-py for invasive bladder cancer: What dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys. 2006; 64: 1168-73.
55. Kob D, Arndt J, Kriester A, Schwenk M, Kloetzer KH: Results of percutaneous radiotherapy of bladder cancer using 1 and 2 series of irradiation. Strahlentherapie. 1985; 161: 673-7.
56. Cole DJ, Durrant KR, Roberts JT, Dawes PJ, Yosef H, Hopewell JW: A pilot study of accelerated fractionation in the radiotherapy of invasive carcinoma of the bladder. Br J Radiol. 1992; 65: 792-8.
57. Nãslund I, Nilsson B, Littbrand B: Hyperfractionated radio-therapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. Acta Oncol. 1994; 33: 397-402.
58. Stuschke M, Thames HD: Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys. 1997; 37: 259-67.
59. Horwich A, Dearnaley D, Huddart R, Graham J, Bessell E, Mason M, et al.: A randomised trial of accelerated radio-therapy for localised invasive bladder cancer. Radiother Oncol. 2005; 75: 34-43.
60. Kob D, Arndt J, Kriester A, Schwenk M, Kloetzer KH: Results of percutaneous radiotherapy of bladder cancer using 1 and 2 series of irradiation. Strahlentherapie. 1985; 161: 673-7.